DISCOVER TYVASO DPI

Learn more
Skip to main content
SELECT A CONDITION
PATIENT SUPPORT PROGRAM
SELECT A CONDITION
PATIENT SUPPORT PROGRAM
Background photo of air particle

CLINICAL FINDINGS

CLINICAL
FINDINGS

TYVASO May Help You
Do What Matters Most

In a clinical study, people who added TYVASO to their current PAH medicine walked farther, improving their 6MWD* in as soon as 6 weeks.†

Portrait of woman using the TYVASO Inhalation System Portrait of woman using the TYVASO Inhalation System
Tyvaso 6-minute walk test clinical study improvements Tyvaso 6-minute walk test clinical study improvements

*6-minute walk distance (6MWD) is a test to see how far you can walk in 6 minutes.
†In the 12-week clinical study of TYVASO, people taking an oral PAH medicine (bosentan or sildenafil) completed a 6-minute walk test at the beginning and end of the study.

Do More in Your Day

When you add TYVASO to your current treatment, you may be able to do things like:

Examples of things you may be able to do when you add Tyvaso to your current treatment. Examples of things you may be able to do when you add Tyvaso to your current treatment.

Continuing the Study

After the 12-week clinical study was over, patients who received TYVASO could continue taking it, and patients who had initially received placebo could start on TYVASO.

Nearly all of the patients who completed the initial study (97%) decided to continue as part of the long-term follow-up study.

Nearly all of the patients who completed the initial study (97%) decided to continue as part of the long-term follow-up study.

During that study, researchers followed patients to understand the dosing and safety of TYVASO. They also observed changes in their 6MWD, their ability to be active, and their rate of survival.

Patients Who Took TYVASO in the Clinical Study and Continued to Be Observed…

Tyvaso improvements found in a long-term follow-up study
Tyvaso improvements found in a long-term follow-up study

It’s important to note that in this study, all of the patients were taking TYVASO, and no comparison was made to people who were not taking TYVASO. So, it’s hard to determine for sure if these results are because of TYVASO.

TYVASO Nebulizer Treatment Tracker

Your personal diary for keeping track of your treatment sessions. See how TYVASO fits into your daily life.

DOWNLOAD TREATMENT TRACKER

You May Have Side Effects

Talk to your healthcare provider and click below to learn more about potential side effects.

WHAT SHOULD I KNOW?

IMPORTANT SAFETY
INFORMATION

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
EXPAND

IMPORTANT SAFETY
INFORMATION

COLLAPSE

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
  • Have asthma or chronic obstructive pulmonary disease (COPD)
  • Are pregnant or plan to become pregnant. It is not known if either product will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if either product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Either product and other medicines may affect each other.

Especially tell your healthcare provider if you take:

  • Medicines used to treat high blood pressure or heart disease
  • Medicines that decrease blood clotting (anticoagulants)
  • Water pills (diuretics)
  • Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of TYVASO or TYVASO DPI?

Both products can cause serious side effects, including:

  • Low blood pressure (symptomatic hypotension). If you have low blood pressure, either product may lower your blood pressure more.
  • Bleeding problems. Either product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of both products are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking TYVASO or TYVASO DPI because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at 

You are now leaving the Tyvaso.com website

This link will take you to a site maintained by a third party who is solely responsible for the site’s content. Click CONTINUE to proceed or CLOSE to return to www.TYVASO.com.

CONTINUE
www.fda.gov/MedWatch

or call 1-800-FDA-1088.

What are TYVASO and TYVASO DPI?

TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prescription medicines used in adults to treat:

  • Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO or TYVASO DPI can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking TYVASO or TYVASO DPI. It is not known if TYVASO or TYVASO DPI is safe and effective in children under 18 years of age.
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. TYVASO or TYVASO DPI can improve the ability to exercise.

The risk information provided here is not comprehensive. To learn more about TYVASO or TYVASO DPI, talk with your healthcare provider. Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI® Inhalation Powder, and additional information at www.TYVASO.com or call 1-844-UNITHER (1-844-864-8437).


TYVISIconSEP2024

PAH=pulmonary arterial hypertension.

Drug Discard Program Privacy Policy Terms of Use Contact Us Site Map

TYVASO and TYVASO DPI are registered trademarks of United Therapeutics Corporation.

All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.

© 2024 United Therapeutics Corporation. All rights reserved. US/TYV/0798